Figure 5.

Effects of sCD40L and ASA on platelet aggregation in response to suboptimal doses of agonists. Washed human platelets (250×10⁶/mL) were left untreated or pretreated with ASA (30 μmol/L) for 5 minutes at 37°C. In (A) sCD40L (1000 ng/mL) was used as the platelet agonist, whereas in B and C, platelets were preincubated with sCD40L or not for 30 minutes. Platelet aggregation was induced with suboptimal doses of collagen (0.25 μg/mL, B) or thrombin (0.025 U/mL, C). Histograms represent medians of aggregation percentages (n=25, median±IQR). *P<0.01 vs other treatments (Kruskal–Wallis followed by Dunn's post hoc test). ASA indicates acetylsalicylic acid; IQR, interquartile range; sCD40L, soluble CD40L.